Stratagene Shares Rise on Agilent Acquisition Pact | GenomeWeb
Shares in Stratagene rose 28.8 percent for the four-day trading week ended Tuesday after Agilent signed a deal to buy the firm for $10.94 a share (see related article this issue). The acquisition price represents a 28 percent premium over Stratagene’s closing price the day before the deal was announced.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.